These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 17365228)

  • 21. A note on the conservativeness of the confidence interval approach for the selection of non-inferiority margin in the two-arm active-control trial.
    Sankoh AJ
    Stat Med; 2008 Aug; 27(19):3732-42. PubMed ID: 18407575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On non-inferiority analysis based on delta-method confidence intervals.
    Rothmann MD; Tsou HH
    J Biopharm Stat; 2003 Aug; 13(3):565-83. PubMed ID: 12921402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Likelihood ratio and a Bayesian approach were superior to standard noninferiority analysis when the noninferiority margin varied with the control event rate.
    Kim MY; Xue X
    J Clin Epidemiol; 2004 Dec; 57(12):1253-61. PubMed ID: 15617951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Some fundamental issues with non-inferiority testing in active controlled trials.
    James Hung HM; Wang SJ; Tsong Y; Lawrence J; O'Neil RT
    Stat Med; 2003 Jan; 22(2):213-25. PubMed ID: 12520558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A covariate-adjustment regression model approach to noninferiority margin definition.
    Nie L; Soon G
    Stat Med; 2010 May; 29(10):1107-13. PubMed ID: 20209669
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Noninferiority hypotheses and choice of noninferiority margin.
    Ng TH
    Stat Med; 2008 Nov; 27(26):5392-406. PubMed ID: 18680173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(2):329-38. PubMed ID: 17365227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Issues on the selection of non-inferiority margin in clinical trials.
    Hou Y; Wu XY; Li K
    Chin Med J (Engl); 2009 Feb; 122(4):466-70. PubMed ID: 19302756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tests of noninferiority via rate difference for three-arm clinical trials with placebo.
    Tang ML; Tang NS
    J Biopharm Stat; 2004 May; 14(2):337-47. PubMed ID: 15206531
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Approaches for testing noninferiority in two-arm trials for risk ratio and odds ratio.
    Chowdhury S; Tiwari RC; Ghosh S
    J Biopharm Stat; 2019; 29(3):425-445. PubMed ID: 30744476
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and analysis of a 3-arm noninferiority trial with a prespecified margin for the hazard ratio.
    Hida E; Tango T
    Pharm Stat; 2018 Sep; 17(5):489-503. PubMed ID: 29984524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
    Zhang F; Miyaoka E; Huang F; Tanaka Y
    J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TACT method for non-inferiority testing in active controlled trials.
    Wang SJ; Hung HM
    Stat Med; 2003 Jan; 22(2):227-38. PubMed ID: 12520559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avoiding ambiguity with the Type I error rate in noninferiority trials.
    Kang SH
    J Biopharm Stat; 2016; 26(3):452-65. PubMed ID: 26252624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes.
    Hirotsu C
    Pharm Stat; 2007; 6(3):193-203. PubMed ID: 17879327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.
    Kaul S; Diamond GA
    Prog Cardiovasc Dis; 2007; 49(4):284-99. PubMed ID: 17185116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls.
    Fay MP; Huang CY; Twum-Danso NA
    Clin Trials; 2007; 4(6):598-610. PubMed ID: 18042569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Power and sample size computations in simultaneous tests for non-inferiority based on relative margins.
    Dilba G; Bretz F; Hothorn LA; Guiard V
    Stat Med; 2006 Apr; 25(7):1131-47. PubMed ID: 16217842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables.
    Cheng B; Chow SC; Burt D; Cosmatos D
    J Biopharm Stat; 2008; 18(3):494-501. PubMed ID: 18470758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.